Injectable buprenorphine trades daily dosing for a monthly shot, and its buy-and-bill model is reshaping who prescribes addiction medication and how they are paid.
Key Takeaways
- The delivery method is changing the business: Long-acting injectable buprenorphine replaces a daily pill with a monthly or weekly shot administered by a provider. That turns a prescription into a billable in-office procedure, with different economics from dispensing.
- Uptake is rising fast but unevenly: A 2026 Health Affairs study found injectables were still under 2 percent of buprenorphine starts through 2024, but growing quickly, and concentrated in Medicaid. Medicaid was the payer in 71 percent of injectable episodes.
- Buy-and-bill and the REMS shape access: Providers either purchase the drug and bill after administering it, or order it through a specialty pharmacy, and only REMS-certified settings can dispense it. Those logistics decide which practices can offer it at all.
- The model fits some settings better than others: Injectables solve adherence and diversion concerns and suit jails, hospitals, and criminal-justice settings, but the upfront cost and workflow favor larger operators. The shift rewards scale and infrastructure.
For most of the history of medication treatment for opioid addiction, the daily dose was the whole architecture. Methadone meant a morning trip to a clinic; buprenorphine meant a film under the tongue every day, a prescription to fill, a pill bottle to keep track of, a routine to sustain against the pull of the disease it was treating. The medication worked, but the delivery put the burden of consistency squarely on the patient, and consistency is precisely what addiction erodes.
A newer class of product inverts that arrangement. Long-acting injectable buprenorphine, sold as Sublocade and Brixadi, is administered by a provider as a shot that lasts a week or a month, and for the stretch between injections the patient does not have to do anything at all to stay on their medication.
The clinical logic is straightforward, and the business logic is where it gets interesting. Shifting from a pill a patient picks up to a shot a provider administers does not just change the patient’s experience; it changes who does the work, who bears the cost, and how the treatment is billed, moving addiction medication out of the pharmacy transaction and into the exam room as a clinical service. That shift, still early and uneven, is quietly reshaping the economics of opioid use disorder treatment, and the operators watching it closely are the ones thinking less about the molecule than about the workflow and the reimbursement that come with it.
How Injectable Buprenorphine Changes the Model
The two approved long-acting injectables both deliver buprenorphine, the partial-opioid-agonist mainstay of opioid use disorder treatment, in an extended-release form. Sublocade, approved in 2017, is a monthly subcutaneous injection. Brixadi, approved in 2023, offers both weekly and monthly dosing and can be started more quickly, which makes it useful in acute settings like emergency departments. Both replace the daily self-administered dose with a periodic one given by a clinician, which addresses two persistent problems at once: patients cannot miss doses they do not have to remember, and a medication kept in a clinic cannot be diverted or sold.
That structural change carries the whole story of why these products matter to operators. A daily film is dispensed by a pharmacy and taken home; a long-acting injectable is purchased and administered by a health care provider, which turns the medication into an in-office clinical service with its own billing, its own storage and handling requirements, and its own workflow. The treatment stops being something that happens between a patient and a pharmacy and becomes something that happens in a provider’s office on a schedule the provider controls, a difference that runs through everything from adherence rates to revenue.
What the Uptake Data Shows
That adoption curve is revealing, because it shows a product growing fast from a small base and doing so uneveny. A 2026 study in Health Affairs analyzed nationwide buprenorphine prescription episodes from 2021 through 2024 and found that long-acting injectables accounted for just under 2 percent of buprenorphine treatment starts, a small share, but one rising quickly and varying enormously from state to state. The technology is not close to displacing the daily film. It is establishing a foothold, and the shape of that foothold tells operators where the model is taking root.
Two findings from that study matter most for anyone building around this shift. The first is the payer: by 2024, Medicaid had become the most common payer for injectable episodes, covering 71 percent of them, which locates the growth squarely in the public-insurance population and ties the product’s future to Medicaid coverage and reimbursement policy. The second is the prescriber: advanced practice clinicians such as nurse practitioners wrote most of the injectable prescriptions, a reflection of who actually staffs much of the addiction-treatment workforce, particularly outside major metros, and a reminder that the elimination of the old federal waiver requirement has genuinely broadened the prescriber base. The growth, in other words, is happening in Medicaid, through mid-level clinicians, in some states far more than others.
The Buy-and-Bill Economics
One phrase governs the business of injectables: buy-and-bill, and it describes a model familiar from other provider-administered drugs but new to much of addiction treatment. In the buy-and-bill approach, a practice purchases the injectable in advance, keeps it on hand, administers it, and then bills the payer after the fact, absorbing the upfront cost of the inventory and the risk that a claim is denied. The alternative is to order each dose through a specialty pharmacy that bills the patient’s insurance and ships the drug to the site for administration, which reduces the practice’s cash outlay but adds coordination and delay. Either way, the drug can only be dispensed through a REMS-certified pharmacy or setting, a safety requirement that adds a certification step and narrows the field of who can offer the product at all.
These logistics are not incidental; they are the barrier to entry. At roughly five hundred dollars per weekly injection and two thousand per monthly dose, a small practice that buys and bills is carrying meaningful inventory cost and denial risk, and the REMS certification, cold-chain handling, and billing sophistication all favor organizations with the administrative infrastructure to manage them. This is the same dynamic Acuity has traced across behavioral health, where the fixed costs of compliance and infrastructure increasingly reward scale, and it means the injectable shift, whatever its clinical merits, tilts the field toward larger and better-capitalized operators.
Where the Model Fits Best
Some settings are close to ideal for long-acting injectables, and they cluster where daily dosing is hardest to sustain. Jails and prisons are a leading example, because a monthly injection given before release solves the notorious problem of continuity at a moment when the return to the community carries a sharply elevated overdose risk, and a person leaving custody on a long-acting injectable is protected for weeks without having to find a prescriber immediately. Hospitals and emergency departments are another natural fit, particularly for Brixadi, which can be initiated rapidly, letting a provider start a patient on weeks of medication during a single encounter rather than hoping they follow up. In each case the value is the same: the medication persists through exactly the gaps where patients on daily dosing tend to fall out of treatment.
The fit is worse where the upfront economics or the workflow do not support it. A small independent practice without the capital to stock the drug, the certification to dispense it, or the volume to justify the setup may find the daily film simpler to offer, which is part of why uptake has been uneven and concentrated. The injectable is not a universally superior product so much as a different one, with a different cost structure that suits some organizations and some patients far better than others, and reading that fit correctly is the strategic question for any operator weighing whether to build the capability.
What the Injectable Shift Means for Operators
For treatment organizations, long-acting injectables represent a genuine expansion of what medication treatment can be, and a set of decisions that are as much operational as clinical. Offering them well means building the buy-and-bill or specialty-pharmacy workflow, securing REMS certification, training staff on administration and storage, and negotiating the reimbursement that makes the economics work, none of which is trivial and all of which rewards the operators with the infrastructure to absorb it. Done right, the injectable becomes both a clinical differentiator, particularly for patients who have struggled with daily adherence, and a billable service line with its own revenue.
The larger significance is the direction the shift points. Medication for addiction is moving, slowly and unevenly, from something dispensed to something delivered, from a pharmacy transaction to a clinical procedure with the reimbursement architecture that implies, and the same logic is visible in the collaborative and integrated care models pulling behavioral health toward billable, coordinated services. Injectables will not replace the daily film, and for many patients the film remains the right tool. But the growth is real, the economics are distinct, and the operators who understand that the product is not just a longer-lasting drug but a different business are the ones positioned to build around it as the shift continues.
